# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers

> **NCT03411122** · PHASE1 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Drug-drug Interactions

## Interventions

- **DRUG:** napabucasin
- **DRUG:** cytochrome P450 (CYP450) probe drugs or BCRP transporter substrate

## Key facts

- **NCT ID:** NCT03411122
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-30
- **Primary completion:** 2018-01-23
- **Final completion:** 2018-01-23
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03411122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03411122, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03411122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*